Chimerix

Company

Related News

Artios expands leadership team as alnodesertib moves toward late-stage development

May 05, 2026

Artios added six senior leaders in 2026 as alnodesertib moved toward late-stage development and potential U.S. commercialization. The company is also running a Phase 2 study of ART6043.

Multiple Myeloma Pipeline Expands With 80+ Therapies as Treatment Paradigms Evolve

Mar 20, 2026

The multiple myeloma treatment landscape is rapidly expanding with over 75 companies developing 80+ pipeline therapies, while clinicians navigate evolving questions about transplant timing, quadruplet regimens, and minimal residual disease testing in newly diagnosed patients.